Salute e Benessere

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 19 August 2024– On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the...
Nasdaq GlobeNewswire
19/08/2024

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US…

Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic atrophy BOSTON and LONDON, Aug.19, 2024(GLOBE NEWSWIRE) -- Akari Therapeutics announced today that the company has received positive and constructive Pre-IND (PIND) feedback from the FDA on July 29, 2024, which provides additional clarity on Akari's final Investigational New Drug Application (IND)- enabling preclinical plans, drug...
Nasdaq GlobeNewswire
19/08/2024

Tiziana Life Sciences Appoints New Chief Executive Officer

"We are delighted to welcome Ivor Elrifi as the new CEO of Tiziana Life Sciences," said Gabriele Cerrone, Founder and Executive Chairman of the Board. " Ivor has an invaluable track record in creating substantial value for biotech and pharma companies with his strategic vision in building intellectual property portfolios and transforming the IP into transformative business development deals and M&A transactions. Tiziana looks forward to creating further value with Ivor as we…
Nasdaq GlobeNewswire
19/08/2024

Buyback of Class B shares in Essity during week 33, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
19/08/2024

Nitinotes Appoints Lloyd Diamond as Chief Executive Officer

Mr. Diamond brings more than 30 years of leadership in the medical device industry, having spearheaded significant advancements in orthopedics, endoscopic, and general surgical devices. Most recently, he served as CEO of Pixium Vision S.A., where he led the development of groundbreaking bionic vision systems and strategic partnerships. "We are thrilled to welcome Lloyd to lead Nitinotes into its next chapter of innovation and growth," saidJohn Barr, Chairman of the Board...
PR Newswire
19/08/2024

Invitation to presentation of BioArctic's second quarter report for April - June…

If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast:https://ir.financialhearings.com/bioarctic-q2-report-2024/register If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to...
PR Newswire
19/08/2024

BioSenic S.A.: Transparency notification received from ABO Infinium Americas…

REGULATED INFORMATIONArticle 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, August 19, 2024, 7:00 CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from ABO Infinium Americas OpCo LTD. The details of the transparency notification are set out below and the full text of the...
Nasdaq GlobeNewswire
19/08/2024

Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with…

COPENHAGEN, Denmark, August 17, 2024– Bavarian Nordic A/S (OMX: BAVA) provides an update on plans for securing supply of vaccines to tackle the current mpox outbreak that the Africa Centers for Disease Control and Prevention (Africa CDC) declared as a Public Health Emergency of Continental Security (PHECS) on August 13, 2024 followed by the World Health Organization (WHO) that declared mpox as a Public Health Emergency of International Concern (PHEIC) on August 14, 2024.“Bavarian Nordic...
Nasdaq GlobeNewswire
17/08/2024

Theriva Biologics Announces Reverse Stock Split

Theriva Biologics, Inc.(NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every twenty five (25) shares of common stock, effective as of 12:01 a.m. (Eastern Time) on August 26, 2024 (the “Effective Date”). The Company's common stock will begin...
Nasdaq GlobeNewswire
16/08/2024

Zealand Pharma major shareholder announcement: Bank of America Corporation

Company announcement – No. 40 / 2024 Zealand Pharma major shareholder announcement: Bank of America CorporationCopenhagen, Denmark, 16 August 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports prior receipt on 19 March 2024 and 5 April 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the...
Nasdaq GlobeNewswire
16/08/2024

Major shareholder announcement

Please see the full announcement in PDF Attachments 2024_25_Major_Shareholders_AnnouncementNovozymes B 13 Aug 2024 FinalNovozymes B 02 July 2024 FinalNovozymes B 01 July 2024 FinalNovozymes B 28 June 2024 FinalNovozymes B 21 June 2024 Final
Nasdaq GlobeNewswire
16/08/2024

Remember Aid Heroes this World Humanitarian Day, says Human Appeal

Recent news from the European Commission revealed that 120 million people have been forcibly displaced in the world, marking a historic increase and the twelfth consecutive annual rise in global figures. The UN also estimates that almost 360 people across 72 countries will be in need of humanitarian aid in 2024, reaching record levels. The Global Humanitarian Overview estimates that to meet the need of humanitarian aid, an additional $48.65B is required. Recent news from the European…
PR Newswire
16/08/2024

Genmab Announces Changes to its Executive Committee

Media ReleaseCOPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice President and Chief Technology OfficerBrad Bailey appointed as Executive Vice President and Chief Commercial OfficerAnthony Mancini, Executive Vice President and Chief Operating Officer, will leave Genmab to pursue other opportunities Genmab A/S (Nasdaq:GMAB)today announced changes to its Executive Committee to support Genmab's growth and evolution into a fully integrated...
Nasdaq GlobeNewswire
16/08/2024

Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program…

In a Phase 3 trial, Pfizer and BioNTech's combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectivesThe trial did not meet one of its primary immunogenicity objectives of non-inferiority against the influenza B strain despite obtaining higher influenza A responses and comparable COVID-19 responses versus the comparator vaccinesThe companies are evaluating adjustments to the candidate and will discuss next steps with health...
Nasdaq GlobeNewswire
16/08/2024

De Motu Cordis (DMC) Applauds ARS Pharma's FDA Approval of Neffy®, Expanding…

"We are pleased to see the approval of a needle-free treatment alternative," said Professor John Fraser, Founder, CMO, Director at DMC. "The approval of Neffy® strengthens the motivation for DMC and the broader drug delivery community to continue pushing the boundaries of innovation. We believe that faster epinephrine absorption via inhalation may prove to be a valuable alternative delivery mode not only for anaphylaxis but also for other emergency medical treatments."…
PR Newswire
16/08/2024

Cervical Pillows Market to Reach $6.7 Billion, Globally, by 2033 at 4% CAGR…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A67736 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A67736 Prime Determinants of Growth The global cervical pillows market is experiencing significant growth, driven by various factors such as the noticeable surge in the utilization of cervical pillows. In addition, the increasing prevalence of cervical ailments among senior adults has...
PR Newswire
16/08/2024

Vistin Pharma ASA: Invitation to Q2 2024 conference call

Vistin Pharma ASA will release its second quarter and YTD 2024 results on Friday 23 rdof August 2024. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Friday 23 rdof August at 08:30 CET. There will be a Q&A session following the management discussion.The conference call will be held in English.The second quarter conference call will be available via web and audio through the following access points: Webcast: ...
Nasdaq GlobeNewswire
16/08/2024

Aino Health AB (publ): interim report january-june 2024

This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail.Extending contracts. Improved cash flow. January – June 2024• Net sales were KSEK 12 230 (11 971) • Profit/loss after financial items was KSEK -4 960 (-5 598)• Earnings per share were SEK -0,1 (-0,1)April – June 2024• Net sales were KSEK 6 236 (5 791)• Profit/loss after financial items was KSEK -2 017 (-2 807)• Earnings per share...
Nasdaq GlobeNewswire
16/08/2024

Essity's targets to reach net-zero emissions validated by Science Based Targets…

"Climate change is one of the defining issues of our time, and Essity has made a firm commitment to achieve net zero emissions by 2050. Our progress is driven by a sense of urgency throughout the organization, together with a strong innovation focus, and collaboration with customers, partners, and suppliers." says Magnus Groth, President and CEO of Essity. "Climate change is one of the defining issues of our time, and Essity has made a firm commitment to achieve net zero emissions…
PR Newswire
16/08/2024

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2024 (UNAUDITED)

Company announcement, Helsinki, August 16, 2024 at 9 am (EEST) NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2024 (UNAUDITED)NEXSTIM CONTINUED TO GROW AND IMPROVED ITS PROFITABILITY IN THE FIRST HALF OF THE YEARThe figures in parentheses refer to the previous year's comparative period, unless otherwise stated. January–June 2024 in briefThe company's net sales were EUR 3.2 million (2.5), with an increase of 26.9 %Net sales growth adjusted for currency exchange...
Nasdaq GlobeNewswire
16/08/2024

Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to…

Interim results from clinical study show non-inferiority of immune responses from mpox/smallpox vaccination in adolescents and similar safety profile compared to adults, supporting the extension of current approval in Europe later in 2024.COPENHAGEN, Denmark, August 16, 2024– Bavarian Nordic A/S (OMX: BAVA) has submitted clinical data to the European Medicines Agency (EMA) to support the extension of the IMVANEX ®(MVA-BN ® ) smallpox and mpox vaccine indication to include adolescents...
Nasdaq GlobeNewswire
16/08/2024

Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new…

In June, Navamedic signed a license and supply agreement with Orion Corporation (Orion) to market and sell Flexilev® and OraFID® in Europe. This agreement represents a major milestone in Navamedic's commercialisation strategy for Flexilev®. Orion has paved the way for Parkinson's disease treatment in Europe, making it a strong commercial partner for Navamedic. In June, Navamedic signed a license and supply agreement with Orion Corporation (Orion) to market and sell Flexilev ®and OraFID…
PR Newswire
16/08/2024

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and…

Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023Product revenues for the first six months were $66 million, a 190% increase from the same period last year, with Q2 product revenues contributing $53 millionLicense and other revenues for the first six months increased to $170 million, with Q2 license and other revenues contributing $145 million Adjusted EBITDA in the first six months was $64 million,...
Nasdaq GlobeNewswire
15/08/2024

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual…

LONDON and NEW YORK, Aug.15, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the company will participate in the H.C. Wainwright 4th Annual...
Nasdaq GlobeNewswire
15/08/2024
Altri  Comunicati